Gooch & Housego PLC (LSE: GHH)

Gooch & Housego PLC (LSE: GHH) is a UK-based company listed on the FTSE AIM All-Share, specializing in the production of optoelectronic components, materials, systems, and advanced instrumentation for the life sciences industry. The company operates within three main sectors: Industrial, Aerospace & Defense, and Life Sciences/Bio Photonics. This Report covers the Key Recommendation Rationale, Conclusion, and Recommendation on the stock.

Key Recommendation Rationale – Sell at GBX 596.38

• Resistance near Current levels: GHH’s stock price has breached Resistance (R1) which was stated in the previous report on 12 September 2025 therefore, there can be a possibility of a decline from resistance levels. Considering the market conditions and the price action, it is prudent to exit the stock.
• Continued Weakness in Industrial Markets May Affect Balance of Growth - While Gooch & Housego has delivered decent growth in Aerospace & Defence and Life Sciences, the ongoing softness in industrial markets—including semiconductors and industrial lasers—may impact the Group’s ability to maintain a balanced growth profile across all segments. The decline of 4.9% in Industrial revenue during H1 FY25, even when partially offset by subsea data cable performance, suggests that recovery in these sectors remains uncertain and could take longer than expected.
• Margin Pressure in Life Sciences Highlights Competitive Challenges - Despite a double-digit increase in Life Sciences revenue, operating margins in the segment declined from 14.7% to 12.0% in H1 FY25. This appears to reflect the effects of pricing pressure—both from pre-agreed reductions in high-volume programmes and rising competition from lower-cost overseas providers. If such trends persist, they may dampen profitability expectations in an otherwise promising segment.

Valuation Methodology: Price/ Earnings Approach

Share Price Chart  

GHH Daily Technical Chart, Source - Refinitiv

Conclusion

GHH is expected to trade at a discount, considering Continued Weakness in Industrial Markets, and fears of global slowdown. For conducting the valuation, the following peers have been considered - dotDigital Group PLC (LSE: DOTD), accesso Technology Group PLC (LSE: ACSO) and others.

Given its current trading levels, Margin Pressure in Life Sciences, recent rally in the share price, relative valuation, and associated risks, it is prudent to exit the stock at the current levels. Hence, a ‘Sell’ recommendation is given on the stock at the current Market Price of GBX 596.38 as of 29 September 2025 at 09:10 AM GMT+1.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 29 September 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.